SCHEMBL3562831

SCHEMBL3562831

O=Cc1ccc(N2CCN(c3ccc(-c4ccccc4)cc3)C2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
ROCK2 O75116 2/20 0.47
ROCK1 Q13464 2/20 0.47
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2A6 P11509 1/20 0.42
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41
PRMT1 Q99873 1/20 0.40
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
PRKDC P78527 1/20 0.38
USP2 O75604 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550218 0.84 RAB9A (0.55) MEN1KMT2ANPC1RAB9AROCK2
SCHEMBL18364102 0.78 MEN1 (0.60) MEN1KMT2ANPC1RAB9AROCK2
SCHEMBL5733969 0.78 ALDH1A1 (0.68) TRIM24TRIM33ALDH1A1CYP2A6MGLL
Benzene SCHEMBL28288569 0.78 ALDH1A1 (0.68) TRIM24TRIM33ALDH1A1CYP2A6MGLL
SCHEMBL10969109 0.78 ALDH1A1 (0.68) TRIM24TRIM33ALDH1A1CYP2A6MGLL
SCHEMBL6032 0.78 ALDH1A1 (0.68) TRIM24TRIM33ALDH1A1CYP2A6MGLL
SCHEMBL18363796 0.77 MEN1 (0.58) MEN1KMT2ANPC1RAB9AROCK2
SCHEMBL16381738 0.76 ALDH1A1 (0.59) MEN1KMT2ANPC1TRIM24TRIM33
SCHEMBL3560004 0.75 RAB9A (0.56) MEN1KMT2ANPC1RAB9AROCK2
SCHEMBL3555541 0.75 DRD2 (0.48) MEN1KMT2ANPC1RAB9ATRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
EP-2010524-A2 S1P RECEPTOR MODULATING COMPOUNDS Epix Delaware, Inc. (US) 2009-01-07 EP disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015177-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR2, S1PR5 MEN1 1502/4885KMT2A 2067/4885NPC1 531/4885
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR2, S1PR5 MEN1 1502/4885KMT2A 2067/4885NPC1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.